NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Elacestrant for treating postmenopausal hormone receptor-positive HER2-negative advanced or metastatic breast cancer after 1 or 2 endocrine treatments ID6225

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Menarini Group (elacestrant) Patient/carer groups • Black Health Agency for Equality • Breast Cancer Now • Breast Cancer UK • Cancer Black Care • Cancer Equality • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • MET UP UK • National Hereditary Breast Cancer Helpline • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Healthcare professional groups • Association of Breast Surgery • Association of Cancer Physicians • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Oncology Pharmacy Association • British Society of Interventional Radiology • Cancer Research UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Possible comparator companies • Accord Healthcare (capecitabine, exemestane, everolimus; paclitaxel, tamoxifen) • Amarox (capecitabine) • AstraZeneca (fulvestrant) • Aurobindo Pharma – Milpharm (tamoxifen) • Bristol Myers Squibb Pharmaceuticals (paclitaxel) • Cipla (fulvestrant) • Dr. Reddy's Laboratories (capecitabine, everolimus, fulvestrant) • Eli Lilly (abemaciclib) • Ethypharm (everolimus) • Fresenius Kabi (paclitaxel) • Genesis Pharmaceuticals (tamoxifen)

Consultees	**Commentators (no right to submit or appeal)**
• Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Breast Cancer Group • UK Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS England	• Glenmark Pharmaceuticals (capecitabine, exemestane, fulvestrant) • Hospira UK (paclitaxel) • Medical Valley (fulvestrant) • Morningside Healthcare (capecitabine, exemestane) • Novartis (alpelisib, everolimus, ribociclib) • Pfizer (exemestane, paclitaxel; palbociclib) • Ranbaxy (fulvestrant) • Relonchem (tamoxifen) • Rivopharm (exemestane) • Sandoz (everolimus, fulvestrant) • Seacross Pharmaceuticals (paclitaxel) • Teva UK (everolimus, fulvestrant, paclitaxel; tamoxifen) • Thornton and Ross (fulvestrant) • Tillomed Laboratories (tamoxifen) • Viatris (exemestane, tamoxifen) • Waverley Pharma (capecitabine) • Wockhardt UK (tamoxifen) • Zentiva (exemestane, fulvestrant) <u>Relevant research groups</u> • Against Breast Cancer • Breast Cancer Hope • Cochrane Breast Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Institute for Health Research • Pro-Cancer Research Fund <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

<u>Consultees</u>

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non-company consultees are invited to submit statements relevant to the group they are representing.

